One Shot a Year: The Tiny Biotech That Just Embarrassed AbbVie's $18B Drug

Skyrizi (risankizumab) is the king of this class. It's not just a blockbuster; it's a mega-blockbuster that now accounts for roughly 29% of AbbVie's entire revenue. Its sales more than doubled from $7.8 billion in 2023 to $17.6 billion in 2025. AbbVie expects another 23% jump this year.

So when analysts at Jefferies described Oruka's data as an "outright win over Skyrizi," that's not a throwaway line. That's a $22 billion revenue stream being called into question.

To be clear: this is a cross-trial comparison, not a head-to-head study. Comparing results across different trials is like comparing marathon times run on different courses in different weather. The numbers are directional, not definitive. But the direction is unmistakable.

The Once-a-Year Trick

Efficacy alone isn't what has investors excited. It's the dosing schedule.

Skyrizi requires an injection every 12 weeks after the initial loading period. That's roughly four or five shots a year. ORKA-001 is engineered with modifications to its Fc region (the tail end of the antibody) that dramatically extend how long it sticks around in the bloodstream. In animal studies, its half-life was more than three times longer than Skyrizi's. In humans, early data suggest a half-life of about 100 days.

The upshot: Oruka believes ORKA-001 could work with one injection per year. For patients managing a chronic condition that never truly goes away, the difference between twelve clinic visits and one is enormous. It's the difference between a monthly subscription and an annual membership.

Wall Street's Verdict (So Far)

The analyst notes came in fast and hot.

Jefferies called the efficacy "unprecedented" for an IL-23 inhibitor and modeled peak sales between $5 billion and $10 billion.

Investors Business Daily ran a headline calling Oruka "a small name that just rattled AbbVie's $18 billion franchise."

Skyrizi's installed base across psoriasis, Crohn's disease, and ulcerative colitis is massive. But the competitive overhang just got a lot more real.

The Caveats You Should Know About

Before anyone starts carving Oruka's name on a trophy, some important context.

This was a Phase 2a trial with 63 treated patients. That's a cocktail party, not a stadium. Phase 3 trials typically enroll hundreds or thousands of patients across multiple geographies. Drugs that look stunning in small studies sometimes stumble when tested at scale.

The comparison to Skyrizi is indirect. Until someone runs a proper head-to-head trial (randomized, blinded, same patients), the "outright win" framing is more marketing than science. Oruka has said it plans to release Week 28 efficacy data and 52-week follow-up results in the second half of 2026, which will help answer whether the drug's effects last as long as its pharmacokinetics suggest.

And the competitive landscape isn't standing still. Oral treatments are flooding the psoriasis market: J&J's icotrokinra (the first oral IL-23 pathway drug) was approved in 2026, and Takeda's zasocitinib is gunning for an NDA filing. For some patients, swallowing a pill will always beat getting a shot, no matter how infrequently.

What Happens Next

Oruka is clearly in a hurry. The company has publicly stated it wants to beat Skyrizi's six-year timeline from first-in-human dosing to regulatory filing. That's ambitious for a company that, until this week, most retail investors couldn't pick out of a lineup.

The next data drops to watch: Week 28 results and longer-term durability data, both expected later this year. If the clearance rates hold and the once-yearly dosing hypothesis pans out, Oruka will have one of the most compelling profiles in immunology.

For now, AbbVie's Skyrizi remains the undisputed heavyweight champion, with a revenue base that Oruka can only dream of. But champions get dethroned. It usually starts with a single data readout that nobody saw coming.

This might be that readout.

The FDA Wants to Watch Your Clinical Trial Live. Yes, Really.

The FDA launched a pilot to monitor clinical trial data as it happens, streaming safety and efficacy signals in real time via AI and cloud platforms. The agency explicitly tied the move to staying competitive with China's rapidly modernizing drug approval system.